The Global Research on AntiMicrobial resistance (GRAM) Project is the flagship study of the Oxford GBD (Global Burden of Disease) Group, and aims to provide robust, comprehensive and timely evidence of the burden of antimicrobial resistance (AMR) in 195 countries and territories. The Oxford GBD Group is a partnership between the Big Data Institute (BDI) and Centre for Tropical Medicine and Global Health (CTMGH) at the University of Oxford, and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. GRAM is funded by the UK Department of Health’s Fleming Fund, the Wellcome Trust and the Bill and Melinda Gates Foundation. The overall aim of the GRAM initiative is to strengthen the evidence base on the current global burden of AMR, and how, where and why it is changing. This will provide the essential health intelligence to help drive awareness of AMR, support better surveillance of AMR, and prompt policy action to control AMR, including facilitating antimicrobial stewardship.
See publications:
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050